Cargando…

PB1820: THE EFFECT OF CONVENTIONAL CHEMOTHERAPY AFTER EXITING QUIESCENT STATE IN ACUTE MYELOID LEUKAEMIA

Detalles Bibliográficos
Autores principales:	Láinez-González, Daniel, Alonso-Aguado, Ana Belén, Serrano-López, Juana, Alonso-Dominguez, Juan Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430165/ http://dx.doi.org/10.1097/01.HS9.0000974128.82807.53

Ejemplares similares

PB1827: TWO-LEVEL INHIBITION OF HEDGEHOG SIGNALLING PATHWAY TO EXIT QUIESCENT STATE IN ACUTE MYELOID LEUKAEMIA
por: Láinez-González, Daniel, et al.
Publicado: (2023)

PB1779: DEVELOPING NOVEL SYNERGISTIC DRUG COMBINATIONS WITH VENETOCLAX IN ACUTE MYELOID LEUKAEMIA
por: Harrigan, R., et al.
Publicado: (2022)

PB1901: KARYOTYPIC PROFILE OF CHRONIC MYELOID LEUKAEMIA DIAGNOSED AT TERTIARY LEVEL IN AFGHANISTAN.
por: Haidary, A. M., et al.
Publicado: (2022)

PB1973: MOLECULAR PATTERNS OF RESPONSE AFTER FRONTLINE TREATMENT IN CHRONIC MYELOID LEUKAEMIA (CML).
por: Fernandez-Leyva, Harberth
Publicado: (2023)

PB2164: PROGNOSTIC IMPACT OF ONCOGENE DEK IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Alonso Alonso, R., et al.
Publicado: (2022)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

PB2165: BIOINFORMATIC TOOL FOR IMMUNOMODULATING THE ONCOGENIC TRANSCRIPTOME OF ABC-DLBCLS
por: Rodríguez, M., et al.
Publicado: (2022)

PB1960: SARS-COV-2 OMICRON VARIANT INFECTION AND COVID-19 IN PERSONS WITH CHRONIC MYELOID LEUKAEMIA IN CHINA
por: Cheng, Fang, et al.
Publicado: (2023)

PB1899: OUTCOMES OF PATIENTS UNDERGOING TREATMENT FOR ACUTE MYELOID LEUKAEMIA SHOWING HIGH DEGREE OF PREDICTIVE ACCURACY ON THE EUROPEAN LEUKAEMIA NET (ELN) POST-REMISSION TREATMENT SCORE
por: Richardson, Michelle, et al.
Publicado: (2023)

PB2328: CHRONIC LYMPHATIC LEUKAEMIA (CLL) ASSOCIATED TO ACQUIRED FACTOR V INHIBITOR. A CASE REPORT.
por: Porro Camarero, A., et al.
Publicado: (2022)

PB1978: PATIENT-CENTREDNESS IS PIVOTAL IN A PROSPECTIVE DOSE REDUCTION TRIAL OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
por: Djodikromo, Melissa, et al.
Publicado: (2023)

PB1859: DEFINING T-CELL POPULATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
por: Mora, A., et al.
Publicado: (2022)

PB1867: PURINE ANALOGS ON HAIRY CELL LEUKAEMIA TREATMENT
por: Gomes, G., et al.
Publicado: (2022)

PB1776: ABC TRANSPORTERS AFFECT THE SENSITIVITY OF ACUTE MYELOID LEUKEMIA BLASTS TO CHEMOTHERAPY
por: Cerovska, E., et al.
Publicado: (2022)

PB1868: COMPARISON OF MYELOBLAST CELL PERCENTAGE IN INVESTIGATIONS FOR ACUTE MYELOID LEUKAEMIA INCLUDING FLOW CYTOMETRY, BONE MARROW ASPIRATION AND BONE MARROW TREPHINE
por: Iftikhar, Naml
Publicado: (2023)

PB1892: INCREASED INCIDENCE OF SRSF2 MUTATION WITH AGE INDICATING CLONAL HAEMATOPOIESIS IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA: A SINGLE-CENTER EXPERIENCE
por: Richardson, Michelle, et al.
Publicado: (2023)

PB1940: REAL-LIFE EXPERIENCE OF THE IMMUNE RECONSTITUTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA AND SMALL LYMPHOCYTIC LYMPHOMA TREATED WITH IBRUTINIB.
por: Pérez, Belén Olivares, et al.
Publicado: (2023)

PB1871: HIGH RATES OF INFECTION AND RELATED MORALITY FROM VENETOCLAX THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE RETROSPECTIVE STUDY
por: Chandran, Durga, et al.
Publicado: (2023)

PB1809: CLINICAL TRAJECTORY OF LONG-TERM SURVIVORS OF ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE INDUCTION CHEMOTHERAPY
por: Heering, G., et al.
Publicado: (2022)

PB1921: IS CHEMOIMMUNOTHERAPY (CIT) HISTORY IN THE FIRST LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA?
por: Parbutt, Catherine, et al.
Publicado: (2023)

PB1788: LOW EXPRESSION OF C-TYPE LECTIN-LIKE MOLECULE-1 AND REDUCED OXIDATIVE STRESS DEFINE A SUBSET OF ACUTE MYELOID LEUKAEMIA CELLS WITH ‘STEM-LIKE’ PROPERTIES
por: Sharp, K., et al.
Publicado: (2022)

PB1756: EPIDEMIOLOGY OF ACUTE LYMPHOBLASTIC LEUKAEMIA: A RETROSPECTIVE 6-YEAR SINGLE CENTRE EXPERIENCE
por: Kociaj, Jora, et al.
Publicado: (2023)

PB1829: ARGENTINEAN REAL WORLD EXPERIENCE ON MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY VS INTENSIVE CHEMOTHERAPY TO TREAT FLT3 POSITIVE ACUTE MYELOID LEUKEMIA PATIENTS
por: Navickas, A., et al.
Publicado: (2022)

PB1906: HYPOMETHYLATING AGENT PLUS LOW DOSE VENETOCLAX – A CHEMOTHERAPY-FREE INDUCTION OF ACUTE MYELOID LEUKEMIA TO ACHIEVE COMPLETE REMISSION IN PATIENTS UNFIT FOR CHEMOTHERAPY
por: Kumar, Karthik, et al.
Publicado: (2023)

PB1854: NEXT GENERATION SEQUENCING APPROACHES IN CHRONIC LYMPHOCYTIC LEUKAEMIA: FINDINGS FROM EXTERNAL QUALITY ASSESSMENT
por: Cartwright, A., et al.
Publicado: (2022)

PB1773: MYBLOCK: A MYELOID BLOOD CANCER INITIATIVE
por: Cairns, L., et al.
Publicado: (2022)

PB1782: INTEGRATIVE MOLECULAR SUBTYPES OF ACUTE MYELOID LEUKEMIA
por: Mo, Qianxing, et al.
Publicado: (2023)

PB1832: INFLAMMATION INDUCED COAGULATION IN ACUTE MYELOID LEUKEMIA
por: Ajtić, Olivera Mitrović, et al.
Publicado: (2023)

PB1878: MYELOID SARCOMA IN CHILDREN: ABOUT 9 CASES
por: Yahia, Ameni, et al.
Publicado: (2023)

PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME: A FIRST-IN-CLINIC PHASE 1 STUDY OF GSK3745417
por: Montesinos, Pau, et al.
Publicado: (2023)

PB1787: GADD45A IS OVER-EXPRESSED IN THE BONE MARROW OF PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA REFRACTORY TO INDUCTION CHEMOTHERAPY
por: Bouchla, A., et al.
Publicado: (2022)

PB1830: HIGH EARLY MORTALITY RATES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY IN TWO ACADEMIC CENTERS IN BRAZIL
por: Lisboa Nogueira, F., et al.
Publicado: (2022)

PB1883: IMPLANTATION AND LONG-TERM USE OF PERIPHERALLY-INSERTED CENTRAL CATHETER ARE SAFE IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKAEMIA
por: Szotkowski, Tomáš, et al.
Publicado: (2023)

PB1751: RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R ALL) IN A SINGLE-CENTRE PAEDIATRIC POPULATION
por: Gomes, Guadalupe Ferreira, et al.
Publicado: (2023)

PB1847: ACUTE MYELOID LEUKEMIA – IS IT MORE BESIDES GENETIC ABNORMALITIES?
por: Urbano, M., et al.
Publicado: (2022)

PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS
por: Galdean, S.-M., et al.
Publicado: (2022)

PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS
por: Ramos, M. J., et al.
Publicado: (2022)

PB1832: ARTERIAL THROMBOSIS AND ACUTE MYELOID LEUKEMIA – IS THERE A CONNECTION?
por: Pantic, N., et al.
Publicado: (2022)

PB1807: THE SIGNIFICANCE OF MOLECULAR RISK FACTORS IN ACUTE MYELOID LEUKEMIA
por: Gordienko, Alla, et al.
Publicado: (2023)

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Zeidan, Amer M, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o989ki0b1euq16n1fj9nohni7s